Lataa...
Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
BACKGROUND: Metastatic colorectal cancers (MCRCs) with microsatellite stability (MSS) are resistant to immunotherapy with programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 inhibitors. However, the addition of regorafenib to nivolumab was recently associated with a high response ra...
Tallennettuna:
| Julkaisussa: | Oncologist |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley & Sons, Inc.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7418365/ https://ncbi.nlm.nih.gov/pubmed/32406541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0161 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|